CGT Manufacturing Shifts Toward Industrialization and Process Consolidation
Jun 26, 2026
Cell and gene therapy manufacturing is shifting from scientific feasibility toward industrialization, with industry leaders emphasizing process consolidation, closed workflows, and digital quality systems to enable scalable, reproducible production. Insights from the Advanced Therapies USA conference highlighted that sustainable CGT commercialization depends on manufacturability at scale, with a US$40 million grant program and single-workflow bioreactor data demonstrating practical steps toward that goal.